Petrus Trust Company’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
– Sell
-2,380
Closed -$314K – 93
2025
Q3
$314K Buy
2,380
+472
+25% +$56.6K 0.03% 37
2025
Q2
$202K Sell
1,908
-4,364
-70% -$474K 0.02% 459
2025
Q1
$779K Buy
+6,272
New +$818K 0.07% 70
2023
Q4
– Sell
-3,804
Closed -$492K – 672
2023
Q3
$492K Buy
3,804
+24
+0.6% +$3.2K 0.05% 191
2023
Q2
$469K Buy
3,780
+1,245
+49% +$168K 0.05% 177
2023
Q1
$371K Sell
2,535
-141
-5% -$20.9K 0.05% 200
2022
Q4
$426K Sell
2,676
-10
-0.4% -$1.47K 0.05% 143
2022
Q3
$358K Buy
+2,686
New +$408K 0.05% 53
2020
Q3
– Sell
-1,918
Closed -$212K – 319
2020
Q2
$212K Buy
+1,918
New +$212K 0.02% 171
2020
Q1
– Sell
-2,415
Closed -$361K – 254
2019
Q4
$361K Sell
2,415
-699
-22% -$95.1K 0.06% 89
2019
Q3
$399K Sell
3,114
-168
-5% -$22.5K 0.07% 61
2019
Q2
$468K Sell
3,282
-87
-3% -$11.7K 0.08% 51
2019
Q1
$482K Buy
3,369
+520
+18% +$67.8K 0.09% 51
2018
Q4
$353K Buy
2,849
+1,020
+56% +$151K 0.08% 66
2018
Q3
$308K Buy
+1,829
New +$315K 0.07% 97

Other funds holding JAZZ

Petrus Trust Company's JAZZ Position: Q4 2025 in Review

Petrus Trust Company sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2025, closing a stake of 2,380 shares — an estimated $314K sold.

Petrus Trust Company first reported a position in JAZZ in Q3 2018 and held it in 15 quarters. The position peaked at $779K in Q1 2025. 576 funds tracked by Wall St. Rank hold JAZZ as of Q4 2025.

  • Petrus Trust Company reported no remaining Jazz Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Petrus Trust Company sold 2,380 Jazz Pharmaceuticals shares in Q4 2025, an estimated $314K.
  • Petrus Trust Company first reported a position in Jazz Pharmaceuticals in Q3 2018 and held it in 15 quarters.
  • Petrus Trust Company's Jazz Pharmaceuticals position peaked at $779K in Q1 2025.
  • 576 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2025.

Based on Petrus Trust Company's 13F filing for Q4 2025, filed 17 Feb 2026.